Your Source for Venture Capital and Private Equity Financings

Massinvestor/VC News Daily

VC-funded Company:

X4 Pharmaceuticals
784 Memorial Drive, Suite 140
Cambridge, MA 02139
Phone: 857-529-8300

X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and increase the ability for T-Cells to track and destroy cancer cells. The company's oral small molecule drug candidates inhibit the CXCR4 receptor, a pathway which plays a central role in promoting the immunosuppressive and pro-angiogenic microenvironment of many cancers. X4P-001, the company's lead program, is expected to enter Phase 1/2 testing in refractory clear cell renal cell carcinoma (ccRCC) and other solid tumor indications, and its second program, X4P-002, is in pre-clinical development for oncology applications. X4 was founded and is led by a team with deep product development and commercialization expertise, including several former members of the Genzyme leadership team, and is located in Cambridge, MA.

Key Contact
Alan Walts
Funding Events

12/14/15 $37,500,000 Series A Cormorant Asset Management
Maxim Group
11/16/17 $27,000,000 Series B